TAEK-VAC-HerBy vaccine / Bavarian Nordic - LARVOL DELTA

TAEK-VAC-HerBy-001: TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer (clinicaltrials.gov) - P1 | N=37 | Completed | Sponsor: Bavarian Nordic | N=55 ➔ 37 | Active, not recruiting ➔ Completed

Enrollment change • Trial completion • Breast Cancer • Chordoma • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor

TAEK-VAC-HerBy-001: TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer (clinicaltrials.gov) - P1 | N=55 | Active, not recruiting | Sponsor: Bavarian Nordic | Trial completion date: Jun 2026 ➔ Jan 2025 | Trial primary completion date: Jun 2024 ➔ Feb 2024

Combination therapy • Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Chordoma • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor

BAVARIAN NORDIC DELIVERED RECORD FINANCIAL RESULTS IN 2023 (Bavarian Nordic Press Release) - "Bavarian Nordic A/S...today reports preliminary, unaudited financial results for 2023 and financial guidance for 2024. Furthermore, the Company provides an update on its R&D priorities...Focused R&D priorities to drive sustainable value creation...Bavarian Nordic’s only active immuno-oncology project, TAEK-VAC, has reached a stage where clinical expansion and further investments would be required. The Company has decided to focus its future R&D efforts on infectious diseases through product improvements to remain competitive and new vaccine development. As a consequence, the TAEK-VAC project will not be continued, and the Company has no further plans to invest in immuno-oncology vaccine development."

Discontinued • Oncology • Solid Tumor

TAEK-VAC-HerBy-001: TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer (clinicaltrials.gov) - P1 | N=55 | Active, not recruiting | Sponsor: Bavarian Nordic | Recruiting ➔ Active, not recruiting

Combination therapy • Enrollment closed • Metastases • Breast Cancer • Chordoma • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor

TAEK-VAC-HerBy-001: TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer (clinicaltrials.gov) - P1 | N=55 | Recruiting | Sponsor: Bavarian Nordic | Trial completion date: Jan 2026 ➔ Jun 2026 | Trial primary completion date: Jan 2024 ➔ Jun 2024

Combination therapy • Trial completion date • Trial primary completion date • Breast Cancer • Chordoma • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor

TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer (clinicaltrials.gov) - P1 | N=55 | Recruiting | Sponsor: Bavarian Nordic | Phase classification: P1/2 ➔ P1 | Trial completion date: Dec 2024 ➔ Jan 2026 | Trial primary completion date: Dec 2022 ➔ Jan 2024

Combination therapy • Phase classification • Trial completion date • Trial primary completion date • Breast Cancer • Chordoma • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hepatocellular Cancer • Hepatology • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Liver Cancer • Lung Cancer • Merkel Cell Carcinoma • Neuroendocrine Tumor • Non Small Cell Lung Cancer • Non-melanoma Skin Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Small Cell Lung Cancer • Solid Tumor

Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients (clinicaltrials.gov) - P1/2; N=45; Recruiting; Sponsor: Bavarian Nordic; Not yet recruiting ➔ Recruiting

Clinical • Combination therapy • Enrollment open • Breast Cancer • Esophageal Cancer • Gastric Cancer • GastroEsophageal Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ER • PGR

Phase 1/2 Trial of Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients (clinicaltrials.gov) - P1/2; N=45; Not yet recruiting; Sponsor: Bavarian Nordic

New P1/2 trial